Fourth-generation fluoroquinolones in tuberculosis

  title={Fourth-generation fluoroquinolones in tuberculosis},
  author={Hans L. Rieder},
  journal={The Lancet},
  • H. Rieder
  • Published 4 April 2009
  • Medicine
  • The Lancet

Topics from this paper

Prediction of drug-carrier interactions of PLA and PLGA drug-loaded nanoparticles by molecular dynamics simulations
Abstract In the field of drug delivery, biodegradable polymeric nanoparticles have attracted a great deal of research interest due to their potential as an ideal non-toxic vehicle for the delivery ofExpand
Pathophysiology of Depression and Novel Sources of Phytochemicals for its Treatment – A Systematic Review
The classical monoamine theory of depression is described and connected with the newly found biochemical, genetic and morphological alterations associated with the major depressive disorder and the possibilities to use mesembrine-like alkaloids isolated from Narcissus cv. Expand
IS6110 FAFLP PCR, a tool for genomic mapping enabling investigation of evolutionary relationships of Mycobacterium tuberculosis in resource poor settings
The aim of the thesis is to develop a novel genomic mapping tool using Insertion Element, IS6110 that could aid in epidemiological studies of Mycobacterium tuberculosis complex (MTBC) in low and middle income countries. Expand
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.
It is proposed to reserve the term 'core drug' for the one drug in a regimen that contributes most to relapse-free cure, and to draw lessons from the pioneering work done on shorter MDR-TB treatment regimens and the current knowledge of the bactericidal and sterilizing properties of the drugs to inform the composition of treatment reg regimes. Expand
Spectroscopic and computational (DFT-SCF) investigations on anti tuberculosis activity of Isonicotino hydrazide
The molecular spectroscopic investigations have been carried out to study the antibiotic activity of the Isonicotino hydrazide. The activity of the compositional parts was tested by fundamental modesExpand
Molecular modeling of drug-pathophysiological Mtb protein targets: Synthesis of some 2-thioxo-1, 3-thiazolidin-4-one derivatives as anti-tubercular agents
Abstract Twenty novel 2 - thioxo - 1 , 3 - thiazolidin - 4 - one derivatives ( 5a - 5t ) were synthesized and evaluated for their antitubercular activity. The structure of the compounds was confirmedExpand
Drug development pipeline for the treatment of tuberculosis : Needs , challenges , success and opportunities for the future
Tuberculosis (TB), a leading cause of mortality and morbidity with more than one-third of the world population infected with latent TB andthe worldwide dissemination of multidrug (MDR) andExpand
Machine‐Learning Techniques Applied to Antibacterial Drug Discovery
Two machine‐learning techniques, neural networks and decision trees, that have been used to identify experimentally validated antibiotics are described, and the future directions of this exciting field are described. Expand
Multidrug therapy of Mycobacterium avium subsp. avium infection in experimentally inoculated budgerigars (Melopsittacus undulatus)
The four-month experimental therapy of mycobacteriosis in budgerigars may cause a complete recovery but was not sufficient for the complete recovery of all. Expand
Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity.
The study showed that the risk of development of drug-induced hepatotoxicity following treatment with first line anti-tuberculosis treatment increased with the age of the patient. Expand


WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens and systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation. Expand
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
A phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil found improved culture conversion in the initial phase of tuberculosis treatment. Expand
Recurrence of tuberculosis in a low-incidence setting
In a low-incidence setting of tuberculosis, a control programme incorporating directly observed therapy for active disease resulted in a very low rate of recurrent tuberculosis over a long period of follow-up. Expand
Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study
The chronic features of tuberculosis in these patients suggest that extensively drug-resistant tuberculosis may be acquired through previous treatments that include second-line drugs, according to the treatment strategy recommended by WHO. Expand
Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
  • E. Nathanson, R. Gupta, +6 authors M. Espinal
  • Medicine
  • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 2004
The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied. Expand
Pay dirt: the story of streptomycin. Part I. From Waksman to Waksman.
  • J. H. Comroe
  • Biology, Medicine
  • The American review of respiratory disease
  • 1978
Rifomycin, a new antibiotic; preliminary report.